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Edited by Judit Ova´diAbstract N-acetyl-L-glutamate synthase (NAGS), the ﬁrst en-
zyme of bacterial/plant arginine biosynthesis and an essential
activator of the urea cycle in animals, is, respectively, argi-
nine-inhibited and activated. Site-directed mutagenesis of recom-
binant Pseudomonas aeruginosa NAGS (PaNAGS) delineates
the arginine site in the PaNAGS acetylglutamate kinase-like do-
main, and, by extension, in human NAGS. Key residues for glu-
tamate binding are identiﬁed in the acetyltransferase domain.
However, the acetylglutamate kinase-like domain may modulate
glutamate binding, since one mutation aﬀecting this domain in-
creases the Km for glutamate. The eﬀects on PaNAGS of two
mutations found in human NAGS deﬁciency support the similar-
ity of bacterial and human NAGSs despite their low sequence
identity.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In bacteria and in plants, N-acetyl-L-glutamate synthase
(NAGS) uses AcCoA to N-acetylate glutamate in the ﬁrst step
of arginine synthesis. This enzyme is feed-back inhibited by
arginine [1]. However, in animals, NAGS is activated by argi-
nine, and its only role is to make N-acetyl-L-glutamate (NAG)
for activation of the urea cycle enzyme carbamoyl phosphate
synthetase [2]. Consequently, human NAGS (HuNAGS) deﬁ-
ciency is an inborn error of the urea cycle that causes hyperam-
monaemia [3].
Classical bacterial NAGS was reported in Escherichia coli
(EcNAGS) to be a homohexamer [4]. Each subunit is a
430-residue chain. It has (Fig. 1A–C; http://www.expasy.org)
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doi:10.1016/j.febslet.2008.02.060kinase (AAK) domain) resembling the arginine-inhibitable en-
zyme of the AAK family, N-acetyl-L-glutamate kinase
(NAGK) [5–7]. It also has a C-terminal domain resembling
GNAT-type acetyltransferases [8,9] (called here the GNAT do-
main). Structure determination allowed characterization of the
arginine and the substrate sites of NAGK [6,7], rendering pos-
sible to deﬁne arginine binding signatures that were recognized
also in the AAK domain of bacterial NAGS [7]. We use now
site-directed mutagenesis of recombinant Pseudomonas aeru-
ginosa NAGS (PaNAGS) to conﬁrm the functionality of these
sequences in arginine binding, corroborating the similarity of
the arginine sites of NAGK and NAGS (Fig. 1D). On the basis
of this information we infer the localization of the arginine site
of HuNAGS. Our mutagenesis studies also reveal a key role of
the GNAT domain in binding glutamate. By showing that the
introduction in PaNAGS of two clinical HuNAGS mutations
cause deleterious eﬀects, we support the similarity of PaNAGS
and HuNAGS despite their low sequence identity. Our results
are discussed in the light of crystal structures of Neisseria gon-
orrhoeae NAGS (NgNAGS) that were reported after this pa-
per was submitted [10].2. Materials and methods
Gene PA5204 (http://www.TIGR.org), PCR-ampliﬁed from P. aeru-
ginosa PAO1 genomic DNA, was cloned into the NdeI and XhoI sites
of pET-22b and subjected to site-directed mutagenesis with the Quick-
change kit (from Stratagene) [11]. Mutations K199A, V358A and
G368A were prepared by the overlapping extension method [12]. Prim-
ers used are given in Table 1. PaNAGS was expressed in transformed
BL21(DE3) cells (from Novagene) grown to OD600  0.5. After stand-
ing 45 min at 4 C, 2% (v/v) ethanol and 0.02 mM isopropyl-b-d-thiog-
alactoside were added and the culture was continued overnight at
15 C. All enzyme forms contained the GSLEH6 tail and were puriﬁed
from centrifuged cell sonicates in buﬀer A (20 mM Na phosphate pH
8/1 mM dithiothreitol/0.5 M NaCl/20 mM imidazole), using 0.1-ml
His-SpinTrap centrifugal columns (GE Healthcare) and 0.5 M imidaz-
ole-containing buﬀer A for elution.
Enzyme activity assays were carried out at least in duplicate and
were based on measurement at 412 nm of glutamate-dependent CoA
release using 5,5-dithio-bis(2-nitrobenzoic acid) [9] (e412 nm,
13.6 · 103 M1 cm1 [13]). Fresh enzyme was incubated at 37 C in
20 ll of 0.2 M Tris–HCl pH 9/1 mM AcCoA/20 mM (or, when indi-
cated, 0.1 M) L-glutamate/10 mM MgCl2 and, when used, the indi-
cated arginine concentrations. After 10 min, 0.8 ml 0.2 mM 5,5-
dithio-bis(2-nitrobenzoic acid) in 0.1 M Na phosphate pH 7 was added
and OD412 was determined. Color production was linear with time for
>10 min, and was corrected for 3.7% spontaneous hydrolysis of Ac-
CoA, determined in enzyme-free reactions. Enzyme concentration
was adjusted to prevent >30% consumption of the less abundant sub-
strate. When AcCoA or glutamate were varied (respective variationblished by Elsevier B.V. All rights reserved.
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Fig. 1. Domain composition, sequence alignments and the arginine site of NAGS. (A) Schematic domain organization of PaNAGS, compared with
PaNAGK and with HuNAGS. The regions of HuNAGS are those deﬁned in [2]. (B) and (C) Alignment of PaNAGS with HuNAGS and with either
PaNAGK or the human thialysine Ne-acetyltransferase (HuSSAT). Identical residues are shadowed. The regions corresponding to the signature
sequences for arginine identiﬁed in NAGK and NAGS [7] are boxed. PaNAGS residues mutated here are encircled, and those corresponding to
EcNAGS mutated residues in feed-back resistant enzyme forms [18] are underlined. Clinical mutations are indicated by the amino acid change
encircled below the HuNAGS sequence. Shown as lines (helices) and arrows (b strands) above the AAK domain sequences of PaNAGK and
PaNAGS are the secondary structure elements (named according to [7]) of the PaNAGK [7] and NgNAGS [10] structures (the NgNAGS structure
can be used for PaNAGS given their nearly identical length and important sequence identity/similarity, estimated as 39.4%/60.1% [10]; all the residues
mutated here are conserved in NgNAGS except L353, which is replaced by I). (D) The proposed arginine site of PaNAGS. The NgNAGS crystal
structure is illustrated ([10]; Protein Databank ﬁle 2r8v; http://www.rcsb.org/pdb), but the numbering of the residues for which the side-chains are
shown (which are those mutated here; G275 is highlighted as a black sphere) is that for PaNAGS. Secondary structure elements are named as in
PaNAGK. Arginine is shown in dark grey and is placed in the orientation observed in the arginine site of NAGK [7]. Dotted lines mark polar
interactions between enzyme residues and the inhibitor.
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were ﬁxed, respectively, at 20 mM (or, when indicated, at 0.1 M) and1 mM. Program GraphPadPrism (GraphPad Software, San Diego)
was used to ﬁt the results to hyperbolic kinetics, or, in the presence
Table 1
Synthetic oligonucleotides used
Primer Mutation Direction Sequencea
1b WT Forward 5 0-GCTTTCCCCCATATGCCCGACTACG-3 0
2c WT Reverse 5 0-GGACGCCTCGAGGGATCCCAGGCTCTTCTCG-30
3 Y14A Forward 5 0-CACGCTTCGCCCGCCATCAACTCGCACCGG-30
4 Y14A Reverse 5 0-GTGCGAGTTGATGGCGGGCGAAGCGTGACG-30
5 G146C Forward 5 0-CTATCACCATACCTGTGAGGTCCGTCGCATCG-30
6 G146C Reverse 5 0-GCGACGGACCTCACAGGTATGGTGATAGTC-30
7 K199A Forward 5 0-GGAAGCGGAAGCCCTGATTCTCTACGG-30
8 K199A Reverse 5 0-GTAGAGAATCAGGGCTTCCGCTTCCAGG-30
9 E269A Forward 5 0-CTGCTCAGCGCACTATTCACCCGCACC-30
10 E269A Reverse 5 0-GCGGGTGAATAGTGCGCTGAGCAGCG-3 0
11 G275A Forward 5 0-CACCCGCACCGCCAACGGCACCCTGGTC-30
12 G275A Reverse 5 0-CAGGGTGCCGTTGGCGGTGCGGGTGAATAG-30
13 C339A Forward 5 0-GAAGGGCTGATCATCGCCGCCGCCGCGCTCTACCCG-3 0
14 C339A Reverse 5 0-GTAGAGCGCGGCGGCGGCGATGATCAGCCCTTCG-3 0
15 E352A Forward 5 0-CCGAGGCGGGCGCGCTGGCCTGTCTGGCG-3 0
16 E352A Reverse 5 0-CAGACAGGCCAGCGCGCCCGCCTCGGAATC-30
17 E352D Forward 5 0-CCGAGGCGGGCGATCTGGCCTGTCTGGCG-30
18 E352D Reverse 5 0-CAGACAGGCCAGATCGCCCGCCTCGGAATC-30
19 L353V Forward 5 0-CGGGCGAGGTGGCCTGTCTGGCGGTCAAC-3 0
20 L353V Reverse 5 0-GACCGCCAGACAGGCCACCTCGCCCGCC-3 0
21 V358A Forward 5 0-CTGTCTGGCGGCCAACCCGGAGTAC-30
22 V358A Reverse 5 0-CTCCGGGTTGGCCGCCAGACAGGC-30
23 G368A Forward 5 0-CGGCGGGCGTGCAGACGAACTGCTGGAGC-3 0
24 G368A Reverse 5 0-CCAGCAGTTCGTCTGCACGCCCGCCGTG-30
aMutated bases are underlined. The portions of primers 1 and 2 shown in italic lettering correspond to the beginning and to the end of the open
reading frame.
bIncludes an NdeI site at the initiator ATG (in bold type).
cIncludes a XhoI site (in bold type) and abolishes termination, to allow incorporation of the tail GSLEH6.
E. Sancho-Vaello et al. / FEBS Letters 582 (2008) 1081–1086 1083of arginine, to sigmoidal kinetics. For arginine inhibition, the
data were ﬁtted to the following expression: v ¼ Aþ B
ð1 ½ArgN=ðIN0:5 þ ½ArgN ÞÞ; v and A are activities at a given [Arg]
and at [Arg] =1; B, activity fall caused by [Arg] =1; I0.5, half-inhib-
itory [Arg]; N, Hill coeﬃcient. Protein was determined by the Bradford
assay [14] using a commercial reagent (from Bio Rad) and bovine ser-
um albumin as standard.3. Results
3.1. Production and properties of recombinant PaNAGS
Wild-type and mutant PaNAGS forms were expressed abun-
dantly and were puriﬁed to essential homogeneity (Fig. 2).
Protein mobility in SDS–PAGE (Fig. 2) agreed with se-
quence-deduced masses (wild-type PaNAGS, 49068 Da). As66
45
36
29
24
20
14
C3
39
A
W
T
Y1
4A
K
19
9A
E2
69
A
G
27
5A
G
14
6C
StkDa S
66
45
36
29
24
20
14
kDa
Fig. 2. Coomassie-stained SDS–PAGE (15% polyacrylamide gel) of puriﬁed w
for E352A (central gel) and for wild-type (gel on the right), were used for poly
mass markers (St). Markers masses are given at the sides in kDa.expected, the wild-type protein catalyzed (Vmax P 24 U mg
1
at 37 C) L-glutamate-dependent, but not L-aspartate- or L-
glutamine-dependent (using 20 mM of these amino acids)
CoA release from AcCoA. The concentration-dependency of
the activity was hyperbolic for both substrates (Fig. 3A and
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with sigmoidal kinetics (Fig. 3C and Table 2) and it rendered
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(Table 2) for arginine and for glutamate (in the presence of
0.5 mM arginine) suggests that P 2 arginine and glutamate
sites exist per enzyme molecule. PaNAGS was eluted in fast
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23 C (in 50 mM Tris–HCl, pH 7.5/0.15 M NaCl), as a sym-
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1084 E. Sancho-Vaello et al. / FEBS Letters 582 (2008) 1081–1086presence or absence of 10 mM arginine. The mass estimates
(range 280–296 kDa) indicate that PaNAGS is a non-dissociat-
ing hexamer.
3.2. Eﬀects of putative arginine site mutations
Alanine mutagenesis of any of four residues of the PaNAGS
AAK domain arginine signatures (boxed in Fig. 1B) [7] drasti-
cally increased the I0.5 for arginine, with virtual inhibition abo-
lition by the E269A and G275A mutations, and with 50–60-
fold I0.5 increases triggered by Y14A and K199A (Fig. 3C and
Table 2). This eﬀect was highly selective: these mutations chan-
ged little the substrate kinetic parameters (Table 2) and the
mutant enzyme forms remained hexameric (shown by gel ﬁltra-
tion).3.3. Eﬀects of GNAT domain mutations
GNAT domain mutations aﬀected little arginine inhibition,
but some of them greatly inﬂuenced substrate kinetics (Table
2). C339 and E352 (Fig. 1C), which are conserved in bacterial
NAGSs, appeared candidates for being acceptors of, respec-
tively, the acetyl group of AcCoA or the proton of the gluta-
mate amino group (this last role was suggested by that of
E173 of yeast histone acetyltransferase [16]). These roles were
excluded by the relatively modest magnitude of the decreases
in the apparent Vmax estimated for the C339A and E352A/D
mutations (Fig 3A and B and Table 2). However, E352 ap-
pears to impair very importantly glutamate binding, since
the E352A/D mutations dramatically increased KGlum (Fig. 3B
and Table 2). In addition, these mutations increased 3-fold
(Table 2) K AcCoAm . Mutation to alanine of the invariant puta-
tive AcCoA-binding residues [17] V358 and G368 modestly in-
creased K AcCoAm , but the V358A mutation, similarly to the
E352A/D mutations, drastically increased KGlum (Fig. 3B and
Table 2) and decreased modestly (3-fold) Vmax (Table 2).
3.4. The eﬀects of clinical mutations highlight the similarity of
PaNAGS and HuNAGS
The mutation L442V was found in a late-onset patient and
decreased 50% the activity of in vitro expressed HuNAGS
[3]. We introduced the corresponding mutation L353V in Pa-
NAGS (mapping in the GNAT domain) and observed merely
a 2.3-fold increase in K AcCoAm (Table 2), justifying the fact
that the deﬁciency was partial. In contrast, the G236C clinical
mutation, for which the eﬀects remain uncharacterized in
HuNAGS, when replicated in PaNAGS (G146C mutation,
mapping in the AAK domain) caused a large increase (24-
fold; Table 2 and Fig. 3B) in KGlum and a 3-fold decrease in
Vmax (Table 2). Thus, this mutation certainly appears dis-
ease-causing, and should be associated with a severe pheno-
type. These observations support the similarity of HuNAGS
and PaNAGS despite their limited sequence similarity, illus-
trating the value of PaNAGS as a model for testing the path-
ogenicity of mutations identiﬁed in HuNAGS deﬁciency.4. Discussion
Our results with GNAT domain mutations, although not
very disruptive for catalysis or for AcCoA binding, point to
the involvement of this domain in both functions, since some
of them trigger substantial (although modest) increases in
KAcCoAm and/or decreases in Vmax. Further, the mutations aﬀect-
ing E352 and V358 reveal a crucial role of the GNAT domain
in glutamate binding. These GNAT domain functions agree
with the ﬁnding in the crystal structures of NgNAGS [10] of
GNAT domain-bound AcCoA or CoA and acetylglutamate.
The important hampering of glutamate binding by the
E352A/D and V358A mutations is consistent with the observa-
tions that in the NgNAGS structure the corresponding resi-
dues E353 and V359, respectively, ﬁx or are only 3–2
residues downstream from the acetylglutamate-interacting res-
idues R416 or C356-L357. The increase in K Glum and decrease
in Vmax triggered by the AAK domain mutation G146C ap-
pear indirect eﬀects, since in the NgNAGS crystal structure
[10] G148 (corresponding to G146 of PaNAGS) is at the base
of a protruding superﬁcial stem loop (residues 134–145,
NgNAGS numbering) of the AAK domain that interacts with
Table 2
Kinetic parameters for wild-type and mutant PaNAGS
Enzyme form Kinetic parameters for
AcCoA L-Glutamate L-Arginine
V[AcCoA]=1 (U mg1) Kappm (mM) V
[Glu]=1 (U mg1) Kappm (mM) Inhibmax (%) I0.5 (mM) Hill coeﬃcient
WT 24.0 ± 1.2 0.8 ± 0.1 17.3 ± 0.4 5.0 ± 0.4 90 ± 2 0.55 ± 0.03 2.1 ± 0.3
Mutations aﬀecting the putative arginine site
Y14A 25.7 ± 1.1 1.1 ± 0.1 17.9 ± 1.2 11.9 ± 1.6 91 ± 2 27 ± 2 1.3 ± 0.1
K199A 21.8 ± 0.8 1.0 ± 0.1 11.6 ± 1.7 6.7 ± 0.7 91 ± 3 33 ± 3 1.4 ± 0.3
E269A 26.5 ± 0.8 0.9 ± 0.1 20.6 ± 1.1 7.9 ± 1.0 (90)a 127 ± 115 2.6 ± 2.4
G275A 22.4 ± 0.6 0.9 ± 0.1 14.4 ± 2.9 5.4 ± 0.1 (90)a 165 ± 27 (2.1)a
Mutations aﬀecting the GNAT domain
C339A 11.8 ± 0.5 0.7 ± 0.1 7.8 ± 0.6 12.9 ± 0.8 73 ± 5 0.43 ± 0.05 2.4 ± 0.5
E352A 0.83 ± 0.23b 2.3 ± 1.3b 8.3 ± 1.9c 557 ± 176c 79 ± 5b 0.81 ± 0.09b 1.3 ± 0.2
E352D 3.65 ± 0.43b 2.7 ± 0.6b 6.8 ± 0.3c 438 ± 29c 98 ± 9b 0.72 ± 0.15b 1.0 ± 0.2
V358A 1.80 ± 0.20 1.2 ± 0.4 6.3 ± 0.9c 342 ± 80c 72 ± 3 1.00 ± 0.10 2.5 ± 0.6
G368A 27.7 ± 1.5 1.9 ± 0.2 18.6 ± 2.1 11.8 ± 2.1 88 ± 4 0.30 ± 0.03 1.9 ± 0.3
Mutations corresponding to clinical mutations
G146C 1.34 ± 0.08 0.9 ± 0.2 5.9 ± 0.4c 120 ± 20c ND ND ND
L353V 20.9 ± 0.7 1.8 ± 0.1 12.5 ± 1.1 5.6 ± 1.1 ND ND ND
Kinetic parameters were determined as indicated in Section 2. Kappm , apparent Km values (20 mM ﬁxed glutamate, unless indicated; 1 mM ﬁxed
AcCoA). Inhibmax, fraction of the activity lost upon addition of [Arg] =1. Standard errors are given. ND, not determined.
aValue ﬁxed at the corresponding value for the wild-type enzyme.
b
L-Glutamate was at a concentration of 0.1 M.
c
L-Glutamate was varied between 0 and 0.35 M.
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participate in the acetylglutamate site. Thus, the AAK domain
might modulate the GNAT domain functions, and this super-
ﬁcial AAK domain stem loop might be involved in this modu-
lation. In agreement with a role of the AAK domain in
increasing the aﬃnity for glutamate, the lack of the AAK do-
main in the NAGS ofMycobacterium tuberculosis is associated
with an extremely low aﬃnity of this enzyme for glutamate [9].
The conservation in NAGK and NAGS of the arginine site
residues mutated here (Fig. 1B), and the selective eﬀects of
these mutations on arginine inhibition, strongly support the
similarity of the arginine sites of NAGK and NAGS, a similar-
ity that is supported also by the presence in NAGS (predicted
for PaNAGS, data not shown; experimentally demonstrated in
[10] for NgNAGS) of the N- and H-helices and the aH-b16
loop (Fig. 1B) that are key elements of the arginine site of
NAGK [7]. EcNAGS mutations aﬀecting H15, Y19, S54,
R58 and G287 (corresponding to respective PaNAGS residues
H10, Y14, S49, R53 and G277), found [18] in feed-back resis-
tant forms of EcNAGS, also support the arginine site pro-
posed here (Fig. 1D): H10 and Y14 belong to the N-helix
part of the site, and G277 to the aH-b16 loop, whereas S49
and R53 belong to the aA-b2 connection (Fig. 1B) that inter-
acts with the N-helix at its entry into the enzyme body [7,10],
conceivably hampering arginine inhibition by altering the N-
helix position. The arginine site can be inferred in HuNAGS
from the alignment with NAGK (Fig. 1B; the sites of arginine
signatures are boxed), with conservation of all the arginine site
residues mutated here except Y14, and of two (three including
conservative replacement) of the mutation-harboring residues
identiﬁed in feed-back resistant EcNAGS [18]. Further, the
clinical mutation V350I of HuNAGS abolished arginine acti-
vation [3], as expected, since it falls in the more C-terminal
arginine signature (Fig. 1B). Nevertheless, an important diﬀer-ence between HuNAGS and PaNAGS that might be related
with the diﬀerent eﬀects of arginine on these enzymes is the
lack of a-helical character, given the presence of eight proline
residues (Fig. 1B), in the N-helix-corresponding region of
HuNAGS.
Acknowledgements: Supported by Grant BFU2004-05159 and by an
Intramural Project of CIBERER-ISCIII. E.S.-V. was a fellow-in-train-
ing of CIBERER and M.L.F.-M. had a postdoctoral I3P contract of
CSIC. We thank Elena Cogollos and Nadine Gougeard (from CIBER-
ER) for technical help.References
[1] Cunin, R., Glansdorﬀ, N., Pie´rard, A. and Stalon, V. (1986)
Biosynthesis and metabolism of arginine in bacteria. Microbiol.
Rev. 50, 314–352.
[2] Caldovic, L. and Tuchman, M. (2003) N-acetylglutamate and its
changing role through evolution. Biochem. J. 372, 279–290.
[3] Caldovic, L., Morizono, H. and Tuchman, M. (2007) Mutations
and polymorphisms in the human N-acetylglutamate synthase
(NAGS) gene. Hum. Mutat. 28, 754–759.
[4] Marvil, D.K. and Leisinger, T. (1977) N-acetylglutamate synthase
of Escherichia coli: puriﬁcation, characterization, and molecular
properties. J. Biol. Chem. 252, 3295–3303.
[5] Gessert, S.F., Kim, J.H., Nargang, F.E. and Weiss, R.L. (1994) A
polyprotein precursor of two mitochondrial enzymes in Neuros-
pora crassa. Gene structure and precursor processing. J. Biol.
Chem. 269, 8189–8203.
[6] Ramo´n-Maiques, S., Marina, A., Gil-Ortiz, F., Fita, I. and
Rubio, V. (2002) Structure of acetylglutamate kinase, a key
enzyme for arginine biosynthesis and a prototype for the amino
acid kinase enzyme family, during catalysis. Structure 10, 329–
342.
[7] Ramo´n-Maiques, S., Ferna´ndez-Murga, M.L., Gil-Ortiz, F.,
Vagin, A., Fita, I. and Rubio, V. (2006) Structural bases of
feed-back control of arginine biosynthesis, revealed by the
structures of two hexameric N-acetylglutamate kinases, from
1086 E. Sancho-Vaello et al. / FEBS Letters 582 (2008) 1081–1086Thermotoga maritima and Pseudomonas aeruginosa. J. Mol. Biol.
356, 695–713.
[8] Neuwald, A.F. and Landsman, D. (1997) GCN5-related histone
N-acetyltransferases belong to a diverse superfamily that
includes the yeast SPT10 protein. Trends Biochem. Sci. 22,
154–155.
[9] Errey, J.C. and Blanchard, J.S. (2005) Functional characteriza-
tion of a novel ArgA from Mycobacterium tuberculosis. J.
Bacteriol. 187, 3039–3044.
[10] Shi, D., Sagar, V., Jin, Z., Yu, X., Caldovic, L., Morizono, H.,
Allewell, N.M. and Tuchman, M. (in press) The crystal structure
of N-acetyl-L-glutamate synthase from Neisseria gonorrhoeae
provides insights into mechanisms of catalysis and regulation. J.
Biol Chem.
[11] Marco-Marı´n, C., Ramo´n-Maiques, S., Tava´rez, S. and Rubio, V.
(2003) Site-directed mutagenesis of Escherichia coli acetylgluta-
mate kinase and aspartokinase III probes the catalytic and
substrate-binding mechanisms of these amino acid kinase family
enzymes and allows three-dimensional modelling of aspartokin-
ase. J. Mol. Biol. 334, 459–476.
[12] Pe´rez-Arellano, I., Rubio, V. and Cervera, J. (2006) Mapping
active site residues in glutamate-5-kinase. The substrate glutamateand the feed-back inhibitor proline bind at overlapping sites.
FEBS Lett. 580, 6247–6253.
[13] Ellman, G.L. (1959) Tissue sulfhydryl groups. Arch. Biochem.
Biophys. 82, 70–77.
[14] Bradford, M.M. (1976) A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal. Biochem. 72, 248–254.
[15] Haas, D., Kurer, V. and Leisinger, T. (1972) N-acetylglutamate
synthetase of Pseudomonas aeruginosa. An assay in vitro and
feedback inhibition by arginine. Eur. J. Biochem. 31, 290–295.
[16] Langer, M.R., Tanner, K.G. and Denu, J.M. (2001) Mutational
analysis of conserved residues in the GCN5 family of histone
acetyltransferases. J. Biol. Chem. 276, 31321–31331.
[17] Han, B.W., Bingman, C.A., Wesenberg, G.E. and Phillips Jr.,
G.N. (2006) Crystal structure of Homo sapiens thialysine Ne-
acetyltransferase (HsSSAT2) in complex with acetyl coenzyme A.
Proteins 64, 288–293.
[18] Rajagopal, B.S., DePonte 3rd, J., Tuchman, M. and Malamy,
M.H. (1998) Use of inducible feedback-resistant N-acetylgluta-
mate synthetase (argA) genes for enhanced arginine biosynthesis
by genetically engineered Escherichia coli K-12 strains. Appl.
Environ. Microbiol. 64, 1805–1811.
